More Study Needed of Possible Carcinogenesis of Winter Gas Additive

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 8
Volume 5
Issue 8

WASHINGTON--Although the chemical MTBE, added to gasoline in the winter to reduce the emission of carbon monoxide, does not pose a substantial human health risk, more study needs to be undertaken to assess both short- and long-term health effects, a National Research Council (NRC) committee said in its review of a draft of a federal report.

WASHINGTON--Although the chemical MTBE, added to gasoline in thewinter to reduce the emission of carbon monoxide, does not posea substantial human health risk, more study needs to be undertakento assess both short- and long-term health effects, a NationalResearch Council (NRC) committee said in its review of a draftof a federal report.

The federal study assessed the effects of methyl-tertiary-butylether (MTBE) on air and water quality, motor vehicles (fuel economyand engine performance), and public health.

In areas that have not met air quality standards for carbon monoxide,federal law requires the use of additives that increase oxygenlevels in gas during winter months when lower temperatures tendto cause vehicles to emit more carbon monoxide. However, availabledata indicate that oxygenated fuels reduce winter air levels ofcarbon monoxide by as little as 0% to about 10%, the committeesaid.

The NRC committee disagreed with the report's conclusion thatonly a small percentage of the population may be sensitive toMTBE, citing studies showing an increase in health problems amongworkers exposed to MTBE on the job.

In addition, the panel said, cancer estimates for MTBE were basedon animal models and should not be taken as conclusive. The committeerecommended that further investigations be made into MTBE as apotential carcinogen.

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content